new_0222_0299|ALGS|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0299|ALGS|1|Aligos Therapeutics Inc Total Current Assets (Quarterly) (USD)|Aligos Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Aligos Therapeutics Inc Inventories (Quarterly) (USD)|Aligos Therapeutics Inc Net PP&E (Quarterly) (USD)|Aligos Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Aligos Therapeutics Inc Total Liabilities (Quarterly) (USD)|Aligos Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Aligos Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Aligos Therapeutics Inc Total Deposits (Quarterly) (USD)|Aligos Therapeutics Inc Book Value (Quarterly) (USD)|Aligos Therapeutics Inc Retained Earnings (Quarterly) (USD)|Aligos Therapeutics Inc Treasury Stock (Quarterly) (USD)|Aligos Therapeutics Inc EV to Revenues|Aligos Therapeutics Inc EV to Earnings|Aligos Therapeutics Inc EV to Free Cash Flow|Aligos Therapeutics Inc EV to Assets (Quarterly)|Aligos Therapeutics Inc PS Ratio|Aligos Therapeutics Inc PE Ratio|Aligos Therapeutics Inc Price to Book Value|Aligos Therapeutics Inc PEG Ratio|Aligos Therapeutics Inc Debt to Equity Ratio|Aligos Therapeutics Inc Dividend Yield|Aligos Therapeutics Inc Shareholder Yield (TTM)|Aligos Therapeutics Inc Percent of Shares Outstanding Short|Aligos Therapeutics Inc Total Receivables (Quarterly) (USD)|Aligos Therapeutics Inc Total Payables (Quarterly) (USD)|Aligos Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Aligos Therapeutics Inc Return on Invested Capital|Aligos Therapeutics Inc Quality Ratio Score|Aligos Therapeutics Inc Momentum Score|Aligos Therapeutics Inc Beta (1Y)|Aligos Therapeutics Inc Sustainable Growth Rate (TTM)|Aligos Therapeutics Inc Institutional Investor Ownership Percentage|Aligos Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Aligos Therapeutics Inc Total Employees (Annual)|Aligos Therapeutics Inc EPS Diluted (Quarterly) (USD)|Aligos Therapeutics Inc SG&A Expense (Quarterly) (USD)|Aligos Therapeutics Inc Shares Outstanding|Aligos Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Aligos Therapeutics Inc Ordinary Shares Number (Quarterly)|Aligos Therapeutics Inc Payout Ratio|Aligos Therapeutics Inc Quick Ratio (Quarterly)|Aligos Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Aligos Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Aligos Therapeutics Inc Effective Tax Rate (TTM)|Aligos Therapeutics Inc Return on Equity|Aligos Therapeutics Inc Net Income (TTM) (USD)|Aligos Therapeutics Inc Revenue (TTM) (USD)|Aligos Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Aligos Therapeutics Inc Revenue (Quarterly) (USD)|Aligos Therapeutics Inc Gross Profit (Quarterly) (USD)|Aligos Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Aligos Therapeutics Inc Net Income (Quarterly) (USD)|Aligos Therapeutics Inc Net Interest Income (Quarterly) (USD)|Aligos Therapeutics Inc Price (USD)|Aligos Therapeutics Inc Total Return Price (USD)|Aligos Therapeutics Inc Enterprise Value (USD)|Aligos Therapeutics Inc 30-Day Average Daily Volume|Aligos Therapeutics Inc 1 Year Price Returns (Daily)|Aligos Therapeutics Inc Short Interest|Aligos Therapeutics Inc PE Ratio (Forward)|Aligos Therapeutics Inc PE Ratio (Forward 1y)|Aligos Therapeutics Inc PS Ratio (Forward)|Aligos Therapeutics Inc PS Ratio (Forward 1y)|Aligos Therapeutics Inc Quarterly EPS Estimates (USD)|Aligos Therapeutics Inc Quarterly Revenue Estimates (USD)|Aligos Therapeutics Inc Quarterly EPS Surprise|Aligos Therapeutics Inc Quarterly Revenue Surprise|Aligos Therapeutics Inc Quarterly Actual EPS (USD)|Aligos Therapeutics Inc Quarterly Actual Revenue (USD)|Aligos Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Aligos Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Aligos Therapeutics Inc Price Target (USD)|Aligos Therapeutics Inc Consensus Recommendation|Aligos Therapeutics Inc Price Target Num Estimates|Aligos Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Aligos Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Aligos Therapeutics Inc Research and Development Expense (Quarterly) (USD)|Aligos Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|Aligos Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|Aligos Therapeutics Inc Land and Improvements (Quarterly) (USD)|Aligos Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|Aligos Therapeutics Inc Other Properties (Quarterly) (USD)|Aligos Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0299|ALGS|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0299|ALGS|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0299|ALGS|5|106.5|106.5||106.5||106.5|106.5|106.5||106.5|106.5||||1.44755244755|91.5|||1.44755244755||91.5|1.44970414201||15.2666666667||106.5|106.5|||31|30.6666666667||30.4444444444|91.375|91.4|91.375|91.375|29.8461538462|91.3333333333|106.5||91.5|91.375|91.25|91.4||91.4|||91.5||91.375|91.375|91.375|1.44970414201|1.44970414201|1.44970414201|1.4498381877|1.43023255814|15.2666666667|||1.45019920319||91.25|91.3333333333|91||91.25|91.25|23.15|28.9375|24.4210526316|9.4693877551|24.4210526316|28.9375|30.8666666667|91.375|91.375||||106.5|106.5||
new_0222_0299|ALGS|6|6|6||6||6|6|6||6|6||||286|2|||286||2|338||30||6|6|||2|3||9|8|5|8|8|13|6|6||2|8|4|5||5|||2||8|8|8|338|338|338|309|86|30|||251||8|9|3||4|4|20|16|19|49|19|16|15|8|8||||6|6||
new_0222_0299|ALGS|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0299|ALGS|201909||||||||||||||||||||||||||||||||||21.9313||-0.6407|2.775||||||-0.6407|||||||||-14.051|-14.051|0.345||||||||||||||||||||||||11.729|0.626|||||||
new_0222_0299|ALGS|201912|120.226|117.663||16.087||211.411|13.818|197.593||-64.891|-66.197|||||||||||||||3.767||||||||21.9313||-0.8291|3.463|||36.8902|||-0.8291|||||||||-18.099|-18.184|0.556||||||||||||||||||||||||14.973|0.644||||10.774|1.611||
new_0222_0299|ALGS|202003||||||||||||||||||||||||||||||||||21.9313||-0.9133|3.419||-0.405||||-0.9133|||||||||-20.029|-20.029|0.468||||||||||||||||||||||||17.302|0.46|||||||
new_0222_0299|ALGS|202006|132.229|128.897||16.212||26.718|15.364|11.354||121.958|-107.023|||||||||||||||3.296|0.002|||||||21.9313|67|-0.9483|4.095|||36.8902|||-0.9483||-0.0356||-73.061|||||-20.856|-20.797|0.374||||||||||||||||||||||||17.176|1.097||||11.783|1.669||
new_0222_0299|ALGS|202009|73.693|70.064||15.646||228.851|19.984|208.867||-136.668|-140.32|||||||||||||5.2978||7.682|||||||19.4208|36.8902|73|-0.9026|4.225|36.8902||36.8902|||-0.9026||-0.0282||-92.307|||||-33.297|-33.297|0.234|14.94|14.94|481.0756|187321.6||1954374|||||||||-0.5593||||30.5|1.5|4|-3.6444|-3.744|17.332|0.885||||11.801|1.692|18.71|
new_0222_0299|ALGS|202012|250.017|243.513||14.908||45.263|30.274|14.989||220.039|-174.74||||-10.0705||||4.5999|||||5.3504||3.313|0.004|||||||36.6062|74|-1.09|6.205|36.6062|0.405|36.6062|||-1.09|-155.542|-0.1476||-108.543|||||-34.201|-34.42||27.65|27.65|768.6484|260801.6667||1958588|||253.1669||-0.8976||-21.4309||-1.09||||31.5|1.5|4|-3.6444||28.081|0.883||||11.734|1.697|28.17|28.74
new_0222_0299|ALGS|202103|219.826|213.415||14.526||39.32|25.231|14.089||195.22|-202.414||||-7.6928|2.7887|||4.4435|||||4.0591||2.81|0.004|||||||37.4343|69|-0.74|5.781|38.1472||38.1472||8.4584|-0.74||-0.1768||-116.188|||0.91||-27.629|-27.674|0.105|22.74|22.74|654.0523|59909.5333||1548431|||216.9753||-0.9405||21.3184||-0.74|0.91|0.9067||35.75|1.5|4|-3.862|-3.8426|22.869|0.873||||12.098|1.733|25.72|27.88
new_0222_0299|ALGS|202106|196.642|190.653||13.753||42.992|30.098|12.894||168.884|-232.232||||-6.5392|2.7755|||4.6109|||||4.4728||1.593|0.004||||||95.7986|37.619|86|-0.79|6.556|38.2001||38.2001||6.3344|-0.79||-0.2338||-125.209|||1.545||-29.79|-29.818|0.072|20.385|20.385|588.056|166961.1||1708596|||194.7746||-0.8117||2.6722||-0.79|1.545|2.4775||36.75|1.5|4|-3.1558|-3.2816|24.554|0.925||||12.015|1.756|14.57|17.05
new_0222_0299|ALGS|202109|248.67|242.185||13.158||46.057|34.78|11.277||217.011|-265.358||||-4.2517|1.5917|||3.0455|||||4.4608||2.601|0.004|||4|1.9573|||42.4|86|-0.78|6.473|42.6118||42.6118||6.9633|-0.78|-78.584|-0.3354||-125.036|||1.537||-32.998|-33.124|0.02|15.51|15.51|418.724|251853.8667|7.7808|1900846|||165.3099||-0.8235||5.2846||-0.78|1.537|2.482||33.8|1.4|5|-3.1618|-3.2862|28.132|0.967||||12.139|1.765|15.93|15.32
new_0222_0299|ALGS|202112|||||||||||||||-2.6773||||2.331|||||5.2997||||||3|0.1472||||||||||||||||||||||||11.87|11.87|263.6693|205612.6667|-57.0705|2258519|||127.6311||-0.8335||||||3.9968||30.8|1.4|5|-3.1539|-3.3576||||||||3.19|2.42
new_0222_0299|ALGS|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.795|||||||||||||||||||||
new_0222_0299|ALGS|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.8|||||||||||||||||||||
new_0222_0299|ALGS|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.765|||||||||||||||||||||
new_0222_0299|ALGS|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.8|||||||||||||||||||||